JP2017524021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524021A5 JP2017524021A5 JP2017509024A JP2017509024A JP2017524021A5 JP 2017524021 A5 JP2017524021 A5 JP 2017524021A5 JP 2017509024 A JP2017509024 A JP 2017509024A JP 2017509024 A JP2017509024 A JP 2017509024A JP 2017524021 A5 JP2017524021 A5 JP 2017524021A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- aripiprazole prodrug
- particles
- surface stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 16
- 229960004372 aripiprazole Drugs 0.000 claims 16
- 239000002245 particle Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 16
- 239000003381 stabilizer Substances 0.000 claims 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims 4
- 238000000149 argon plasma sintering Methods 0.000 claims 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
- 229940068977 polysorbate 20 Drugs 0.000 claims 4
- 230000009977 dual effect Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000001509 sodium citrate Substances 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002612 dispersion medium Substances 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- -1 fatty acid esters Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000012064 sodium phosphate buffer Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000008215 water for injection Substances 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038665P | 2014-08-18 | 2014-08-18 | |
| US62/038,665 | 2014-08-18 | ||
| EP14181328.7 | 2014-08-18 | ||
| EP14181328 | 2014-08-18 | ||
| PCT/EP2015/068872 WO2016026822A1 (en) | 2014-08-18 | 2015-08-17 | Aripiprazole prodrug compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019145176A Division JP6826167B2 (ja) | 2014-08-18 | 2019-08-07 | アリピプラゾールプロドラッグ組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524021A JP2017524021A (ja) | 2017-08-24 |
| JP2017524021A5 true JP2017524021A5 (enExample) | 2018-09-06 |
| JP6571166B2 JP6571166B2 (ja) | 2019-09-04 |
Family
ID=51352472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509024A Active JP6571166B2 (ja) | 2014-08-18 | 2015-08-17 | アリピプラゾールプロドラッグ組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220079939A1 (enExample) |
| EP (2) | EP3182958B2 (enExample) |
| JP (1) | JP6571166B2 (enExample) |
| CN (3) | CN112641785A (enExample) |
| AU (1) | AU2015306198B2 (enExample) |
| BR (1) | BR112017002926A2 (enExample) |
| CA (1) | CA2957762A1 (enExample) |
| CY (1) | CY1124625T1 (enExample) |
| DK (1) | DK3508196T3 (enExample) |
| ES (1) | ES2884849T3 (enExample) |
| HR (1) | HRP20211271T1 (enExample) |
| HU (1) | HUE055711T2 (enExample) |
| IL (2) | IL292079B2 (enExample) |
| MX (1) | MX371417B (enExample) |
| PL (2) | PL3182958T5 (enExample) |
| PT (1) | PT3508196T (enExample) |
| RS (2) | RS58746B2 (enExample) |
| RU (1) | RU2705376C2 (enExample) |
| SI (2) | SI3182958T2 (enExample) |
| SM (2) | SMT202100481T1 (enExample) |
| WO (1) | WO2016026822A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2721270T5 (es) * | 2014-08-18 | 2022-07-21 | Alkermes Pharma Ireland Ltd | Composiciones de profármaco de aripiprazol |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| WO2017143017A1 (en) * | 2016-02-17 | 2017-08-24 | Alkermes Pharma Ireland Limited | Compositions of multiple aripiprazole prodrugs |
| CN110025572A (zh) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | 月桂酰阿立哌唑混悬剂及其制备方法 |
| AU2019230014B2 (en) * | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN110327296B (zh) * | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| TW202317118A (zh) | 2021-06-08 | 2023-05-01 | 日商中外製藥股份有限公司 | 含有二氫嗒-3，5-二酮衍生物的製劑 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| WO1997014407A1 (en) | 1995-10-17 | 1997-04-24 | Research Triangle Pharmaceuticals | Insoluble drug delivery |
| GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| DE60222160T2 (de) * | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| CA2543242C (en) * | 2003-10-23 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof |
| US20070148100A1 (en) * | 2005-09-15 | 2007-06-28 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| ES2639065T5 (es) | 2009-06-25 | 2023-01-30 | Alkermes Pharma Ireland Ltd | Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos |
| PL2685979T3 (pl) * | 2011-03-18 | 2017-02-28 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20 |
| CA2867137C (en) * | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
| AU2013235519C1 (en) * | 2012-03-19 | 2018-04-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
| NZ730571A (en) * | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
-
2015
- 2015-08-17 ES ES19154013T patent/ES2884849T3/es active Active
- 2015-08-17 PT PT191540137T patent/PT3508196T/pt unknown
- 2015-08-17 WO PCT/EP2015/068872 patent/WO2016026822A1/en not_active Ceased
- 2015-08-17 AU AU2015306198A patent/AU2015306198B2/en active Active
- 2015-08-17 DK DK19154013.7T patent/DK3508196T3/da active
- 2015-08-17 HU HUE19154013A patent/HUE055711T2/hu unknown
- 2015-08-17 SM SM20210481T patent/SMT202100481T1/it unknown
- 2015-08-17 CA CA2957762A patent/CA2957762A1/en active Pending
- 2015-08-17 SI SI201530711T patent/SI3182958T2/sl unknown
- 2015-08-17 RS RS20190505A patent/RS58746B2/sr unknown
- 2015-08-17 SM SM20190236T patent/SMT201900236T1/it unknown
- 2015-08-17 CN CN202011448652.3A patent/CN112641785A/zh active Pending
- 2015-08-17 RS RS20210956A patent/RS62232B1/sr unknown
- 2015-08-17 CN CN201580055491.2A patent/CN106794251B/zh active Active
- 2015-08-17 PL PL15750750.0T patent/PL3182958T5/pl unknown
- 2015-08-17 EP EP15750750.0A patent/EP3182958B2/en active Active
- 2015-08-17 EP EP19154013.7A patent/EP3508196B1/en active Active
- 2015-08-17 IL IL292079A patent/IL292079B2/en unknown
- 2015-08-17 RU RU2017108204A patent/RU2705376C2/ru active
- 2015-08-17 JP JP2017509024A patent/JP6571166B2/ja active Active
- 2015-08-17 HR HRP20211271TT patent/HRP20211271T1/hr unknown
- 2015-08-17 PL PL19154013T patent/PL3508196T3/pl unknown
- 2015-08-17 SI SI201531670T patent/SI3508196T1/sl unknown
- 2015-08-17 MX MX2017002029A patent/MX371417B/es active IP Right Grant
- 2015-08-17 CN CN202011416673.7A patent/CN112494492B/zh active Active
- 2015-08-17 BR BR112017002926A patent/BR112017002926A2/pt not_active Application Discontinuation
-
2017
- 2017-02-14 IL IL250607A patent/IL250607B/en unknown
-
2021
- 2021-08-23 CY CY20211100753T patent/CY1124625T1/el unknown
- 2021-10-12 US US17/450,683 patent/US20220079939A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524021A5 (enExample) | ||
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| JP2018048179A5 (enExample) | ||
| RU2020126034A (ru) | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции | |
| CU24504B1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol y un proceso que incluye un paso de granulación para preparar el mismo | |
| JP2016534153A5 (enExample) | ||
| CA2796755C (en) | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative | |
| JP2016510329A5 (enExample) | ||
| HRP20191366T1 (hr) | Injekcijski pripravak | |
| RU2017146716A (ru) | Способ образования наночастиц циклоспорина а/ циклодекстрина | |
| JP2016518403A5 (enExample) | ||
| RU2017108204A (ru) | Композиции пролекарства арипипразола | |
| JP2020511440A5 (enExample) | ||
| JP2020511443A5 (enExample) | ||
| Seshadri et al. | Glucocorticoids inhibit group 3 innate lymphocyte IL-22 production | |
| JP2015520241A5 (enExample) | ||
| EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине | |
| TW201828935A (zh) | 脂肪乳劑及其製造方法、使脂肪乳劑的安定性提升的方法、以及脂肪乳劑的安定性提升劑 | |
| HRP20190642T1 (hr) | Pripravci aripiprazolskog predlijeka | |
| NZ767204B2 (en) | Aripiprazole prodrug compositions | |
| JP2018503629A5 (enExample) | ||
| EA032385B9 (ru) | Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта | |
| MX2022001330A (es) | Composicion oftalmica de bevacizumab. | |
| JP2015522608A5 (enExample) | ||
| MX380536B (es) | Composicion y metodo para tratar la enfermedad de chagas. |